Major boost for Genmab’s candidate drug
US medicines authorities, FDA, have awarded the coveted breakthrough designation to a candidate drug from Danish biotech Genmab. It could lead to an accelerated market entrance for the drug and had an immediate effect on the company share.
by Henrik Tüchsen
The good news keep on coming for Danish biotech Genmab.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab drug earns Fast Track status from the FDA
For abonnenter
Genmab drug approved in Japan
For abonnenter
Genmab launches new technology
For abonnenter
